Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2025 | $5.00 | Buy | B. Riley Securities |
6-K - OKYO Pharma Ltd (0001849296) (Filer)
6-K - OKYO Pharma Ltd (0001849296) (Filer)
6-K - OKYO Pharma Ltd (0001849296) (Filer)
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that urcosimod may have a positive impact on corneal nerve health in patients with neuropathic corneal painCorneal nerve imaging data from the Phase 2 NCP trial were analyzed using in vivo confocal microscopy LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce new
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein c
B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00
4 - OKYO Pharma Ltd (0001849296) (Issuer)
4 - OKYO Pharma Ltd (0001849296) (Issuer)
4 - OKYO Pharma Ltd (0001849296) (Issuer)
LONDON and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 27,051 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,491,746 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein
LONDON and NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces that Panetta Partners Limited, an entity in which Gabriele Cerrone, Executive Chairman has a beneficial interest, has acquired 82,018 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,464,695 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein c
LONDON and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 210,000 of the Company's ordinary shares on NASDAQ, bringing his total holding to 10,382,677 shares. About Urcosimod (Formerly called OK-101)Urcosimod is a lipid conjugated chemerin peptide agonist
LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Operating Officer. Mr Clementi will formally take up the COO role effective September 1, 2023. Mr. Clementi's extensive experience in the pharmaceutical industry and his achievements make him a valuable addition to the OKYO Pharma team. Dr. Clementi has followed a science-driven career path since completing his NIH Training Fellows
LONDON and NEW YORK, Feb. 23, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ((LSE: OKYO, NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces the appointment of Jay S. Pepose, M.D., Ph.D., Founder and Medical Director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine, to OKYO's Scientific Advisory Board (SAB). In this role Dr. Pepose will help guide OKYO's clinical programs for OK-101 for the treatment of DED. The Company anticipates opening its Phase 2 clinical trial of OK-10
LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ((LSE: OKYO, NASDAQ:OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announces that the board of directors of the Company (the "Board" or "Directors"), has appointed PKF Littlejohn LLP ("PKF") as its new independent auditor with immediate effect. The Board has approved the appointment of PKF as the Company's auditor for the financial year ending 31 March 2023. The re-appointment of PKF for the financial year ending 31 March 2024 will be subject to approval by shareh